Skip to main content

  • The addition of evolocumab to maximal tolerated statin therapy improves walking performance in patients with peripheral arterial disease and intermittent claudication (Evol-PAD study)

    • Posted: 10/31/2023
    • Author:

      Leonardo C. Clavijo, Jorge Caro, Jongkyu Choi, Jorge A. Caro, Han Tun, Vincent Rowe, S. Ram Kumar, David M. Shavelle and Ray V. Matthews

    • 2023CRMNews

    Abstract

    Objective

    To test the hypothesis that in patients with peripheral arterial disease (PAD) and claudication, treated with maximal tolerated statin therapy, the addition of a monthly subcutaneous injection of evolocumab for 6 months improves treadmill walking performance.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details